Dynamic change of novel systemic inflammation markers in predicting perinatal outcomes after antenatal corticosteroids in preeclampsia.
Şebnem Karagün, Ahmet Zeki Nessar, Yusuf Dal, Sefanur Gamze Karaca, Mürşide Çevikoğlu Killi, Hamza Yildiz, Ayhan Coşkun
Abstract
Open AccessPreeclampsia (PE) is characterized by systemic inflammation and endothelial dysfunction, contributing to adverse maternal and neonatal outcomes. Antenatal corticosteroids (ACS) therapy is widely used to enhance fetal lung maturity in women at risk of preterm birth. However, little is known about the dynamic changes in maternal inflammatory markers after ACS administration in PE and their potential predictive value for perinatal outcomes. This retrospective cohort study included 206 pregnant women with PE who received ACS therapy due to preterm birth risk. Complete blood count (CBC) parameters and systemic inflammatory indices were recorded before and after ACS. Delta (Δ) values were calculated to reflect the percentage change between pre- and post-ACS measurements. Correlations between Δ inflammatory markers and perinatal outcomes were analyzed, and predictive performance was assessed using receiver operating characteristic (ROC) curve analysis. Following ACS administration, neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and aspartate aminotransferase-to-platelet ratio (APRI) increased significantly, while lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) decreased. Δ mean platelet volume (MPV), Δ aspartate aminotransferase (AST), Δ Lactate Dehydrogenase (LDH), ΔNLR, and ΔAPRI showed low-level positive correlations with umbilical cord blood pH. ROC analysis indicated that ΔMPV ≤ 1.81 (area under the curve (AUC) = 0.664) and ΔAPRI ≤ 1.81 (AUC = 0.605) moderately predicted neonatal intensive care unit (NICU) admission. Dynamic changes in maternal inflammatory markers occur after ACS therapy in preeclamptic pregnancies. ΔMPV and ΔAPRI demonstrated potential predictive value for NICU admission, highlighting their possible clinical utility in risk stratification. These findings provide novel insight into the maternal inflammatory response to ACS in PE and its implications for perinatal outcomes.